Products & ServicesEvent: September 1, 2026
Shinobi Therapeutics designed its lead program NJA-201 from the ground up as an engineered, off-the-shelf, iPSC-derived cell therapy.
Published
Signal category
Products & Services
Quote
“We designed NJA-201 from the ground up to take a different approach. It’s an engineered, off-the-shelf, iPSC-derived cell therapy.”
— Dan Kemp|Shinobi Therapeutics team
Company
- Industry
- Biotechnology Research
- Location
- South San Francisco, US
- Company size
- 39 employees
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
Founded 2023